You are here

Phase 3 Trial Launched to Evaluate Efficacy, Safety, and Tolerability of Albiglutide

ROCKVILLE, Md., Feb. 17 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (NASDAQ:HGSI) today announced that GlaxoSmithKline (NYSE:GSK) has initiated a Phase 3 clinical trial program to evaluate the efficacy, safety and tolerability of Syncria(R) (albiglutide) in the long-term treatment of type 2 diabetes mellitus. As a result, HGS will receive a $9 million milestone payment in the first quarter of 2009.

"We are delighted that GSK has advanced Syncria to Phase 3 development, and we look forward to the future progress of this important program," said H. Thomas Watkins, President and Chief Executive Officer, HGS.

Syncria is the fifth product to which HGS has substantial financial rights that has entered late-stage clinical development. It is a biological product generated from the genetic fusion of human albumin and modified human GLP-1 peptide, and is designed to act throughout the body to help maintain normal blood-sugar levels and to control appetite. Syncria was created by HGS using its proprietary albumin-fusion technology, and licensed to GSK in 2004. HGS is entitled to fees and milestone payments that could amount to as much as $183 million - including $24 million received to date - in addition to single-digit royalties on worldwide sales if Syncria is commercialized.

Source: Human Genome Sciences

Recent Headlines

Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs